What is Augtyro prescribed for?
Augtyro is prescribed for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
What is Augtyro and what does it do?
Augtyro, pronounced Aug-TYE-ro, (generic name: repotrectinib) is a newly FDA-approved medication for treating a specific type of lung cancer called ROS1-positive non-small cell lung cancer (NSCLC).
This cancer affects the lungs and can spread to other parts of the body. Augtyro is designed to help adults with this advanced stage of lung cancer, slowing the disease’s progression and helping to manage its symptoms.
How does Augtyro work?
Augtyro is classified as a kinase inhibitor. Kinases are proteins in the body that control various functions, including cell growth.
In some cancers, these proteins are overactive, leading to rapid and uncontrolled growth of cancer cells.
Augtyro targets these proteins, specifically those causing ROS1-positive NSCLC, thereby slowing down the cancer’s growth and spread.
What did the research discover?
The effectiveness of Augtyro was confirmed through a clinical trial involving patients with ROS1-positive NSCLC.
Patients treated with Augtyro showed significant improvements, with many experiencing a reduction in tumor size.
Specifically, 78.9% of patients who had not previously received ROS1-targeted therapies showed a positive response to Augtyro, meaning their tumors shrank or stopped growing for a significant period.
What are some of the side effects?
The side effects listed are from the product manufacturer. As health scientists, we share this information to keep you informed without causing undue worry. Many side effects diminish over time, and not all patients experience them. If prescribed medication, take it as directed and consult your healthcare professional if you have any concerning side effects.
- Dizziness
- Changes in taste (dysgeusia)
- Numbness or tingling in the hands and feet (peripheral neuropathy)
- Constipation
- Difficulty breathing (dyspnea)
- Unsteadiness when walking (ataxia)
- Tiredness (fatigue)
- Difficulty with thinking or memory (cognitive impairments)
- Muscle weakness
What are the dosage recommendations and how is it prescribed?
Augtyro is taken as a capsule by mouth. The recommended starting dosage is 160 mg once daily for the first 14 days, after which the dosage is increased to 160 mg twice daily. It can be taken with or without food.
Patients are advised to follow their doctor’s instructions closely to ensure the best possible outcome with the treatment.
Source:
- Highlights of Prescribing Information for Augtyro. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf. Accessed 18 July 2024.
- Drug Trials Snapshots: AUGTYRO. FDA. Available from: https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-augtyro. Accessed 18 July 2024.
